This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol®) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Communications Biology Open Access 10 June 2021
Activation of Human T-Helper/Inducer Cell, T-Cytotoxic Cell, B-Cell, and Natural Killer (NK)-Cells and induction of Natural Killer Cell Activity against K562 Chronic Myeloid Leukemia Cells with Modified Citrus Pectin
BMC Complementary and Alternative Medicine Open Access 04 August 2011
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Eliaz I . The potential role of modified citrus pectin in the prevention of cancer metastasis. Clin Pract Altern Med 2002; 2: 177–179.
Raz A, Lotan R . Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metast Rev 1987; 6: 433–452.
Bresalier RS et al. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 1997; 80: 776–787.
Raz A et al. Monoclonal antibodies to endogenous galactose-specific tumor cell lectins. EMBO J 1984; 3: 2979–2983.
Kidd P . A new approach to metastatic cancer prevention: modified citrus pectin (MCP), a unique pectin that blocks cell surface lectins. Altern Med Rev 1996; 1: 4–10.
Naik H, Kalemkerian G . Inhibition of in vitro tumor cell-endothelial adhesion by modified citrus pectin: a pH modified natural complex carbohydrate [abstr]. Proceedings of the Annual Meeting of the American Association of Cancer Research A377, 1995.
Pienta KJ et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87: 348–353.
Nangia-Makker P, Conklin J, Hogan V, Raz A . Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002; 94: 1854–1862.
Schmid HP, McNeal JE, Stamey TC . Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031.
Stamey TA et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–916.
Stamey TA, Kabalin JN . Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141: 1070–1075.
Guess B et al. Using splines to detect changes in PSA doubling times. Prostate 2003; 54: 88–94.
Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.
Roberts SG et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001; 76: 576–581.
Sartor CI et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997; 38: 941–947.
Lee RW, Hanks GE, Hanlan A . Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997; 15: 230–238.
Pollack A, Zagars GK, Kavadi VS . Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994; 74: 670–678.
McLaren DB, McKenzie M, Duncan G, Pickles T . Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early-untreated prostate carcinoma. Cancer 1998; 82: 342–348.
Gross C, Stamey TS, Hancock S, Feldman D . Treatment of early recurrent prostate cancer with 1,25 dihydroxyvitamin D3 (calcitriol). J Urol 1998; 159: 2035–2039.
Beer TM, Lemmon D, Lowe BA, Henner DW . High-dose weekly oral calcitriol in patients with a rising psa after prostatectomy or radiation for prostate carcinoma. Cancer. 2003; 97: 1217–1224.
Beer TM et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123–128.
About this article
Cite this article
Guess, B., Scholz, M., Strum, S. et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis 6, 301–304 (2003). https://doi.org/10.1038/sj.pcan.4500679
This article is cited by
Nature Reviews Drug Discovery (2023)
The influence of surface chemistry upon the textural, thermal and sorption properties of apple-pectin adsorbent materials
Journal of Thermal Analysis and Calorimetry (2023)
Communications Biology (2021)
Current Oncology Reports (2017)
Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide
Clinical & Experimental Metastasis (2013)